To gain further insight into the pathologic implications of loss of ERα-coupled Bmi1 inducing abnormal p16INK4a expression, the relationships between aberrant p16INK4a expression and other factors in breast cancer such as HER2 and Ki-67 were analyzed. Here, CDKN2A is linked to breast cancer.